Subscription business model

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Friday, November 3, 2023

Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,956,764,011 outstanding ordinary shares carrying voting rights (compared to 2,879,124,260 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Sunrun Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023

Customers grew 19% in the third quarter of 2023 compared to the third quarter of 2022.

Key Points: 
  • Customers grew 19% in the third quarter of 2023 compared to the third quarter of 2022.
  • Total revenue was $563.2 million in the third quarter of 2023, down $68.7 million, or 11%, from the third quarter of 2022.
  • During the third quarter of 2023, Sunrun recorded a non-cash goodwill impairment charge of approximately $1.2 billion.
  • Sunrun is hosting a conference call for analysts and investors to discuss its third quarter 2023 results and business outlook at 2:00 p.m. Pacific Time today, November 1, 2023.

Graphene Market: IDTechEx Provides An Outlook for the Coming Decade

Retrieved on: 
Monday, November 6, 2023

This is now changing, and over the next decade, IDTechEx forecast the graphene market to expand in a number of key application areas, reaching a market value of US$1.6 billion by 2034.

Key Points: 
  • This is now changing, and over the next decade, IDTechEx forecast the graphene market to expand in a number of key application areas, reaching a market value of US$1.6 billion by 2034.
  • IDTechEx has covered the graphene market comprehensively for over a decade, providing a detailed independent analysis of the technological and commercial progress of graphene and other 2D materials.
  • The commercialization has been making steady progress, and IDTechEx expects the graphene market to grow significantly over the next decade.
  • For more details on the graphene market, including segmentation by application area, see the IDTechEx market report " Graphene Market & 2D Materials Assessment 2024-2034: Technologies, Markets, Players ".

Graphene Market: IDTechEx Provides An Outlook for the Coming Decade

Retrieved on: 
Monday, November 6, 2023

This is now changing, and over the next decade, IDTechEx forecast the graphene market to expand in a number of key application areas, reaching a market value of US$1.6 billion by 2034.

Key Points: 
  • This is now changing, and over the next decade, IDTechEx forecast the graphene market to expand in a number of key application areas, reaching a market value of US$1.6 billion by 2034.
  • IDTechEx has covered the graphene market comprehensively for over a decade, providing a detailed independent analysis of the technological and commercial progress of graphene and other 2D materials.
  • The commercialization has been making steady progress, and IDTechEx expects the graphene market to grow significantly over the next decade.
  • For more details on the graphene market, including segmentation by application area, see the IDTechEx market report " Graphene Market & 2D Materials Assessment 2024-2034: Technologies, Markets, Players ".

Shutterstock Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, October 31, 2023

Shutterstock cautions investors that non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies.

Key Points: 
  • Shutterstock cautions investors that non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies.
  • Management also believes that providing these non-GAAP financial measures enhances the comparability for investors in assessing Shutterstock's financial reporting.
  • The Company will discuss its third quarter and full year financial results during a teleconference today, October 31, 2023, at 8:30 AM Eastern Time.
  • A webcast replay of the call will be available on the Company's website beginning on October 31, 2023 at approximately 10:30 AM Eastern Time.

Deceptive Short Seller Muddy Waters Once Again Has Its “Facts” Wrong

Retrieved on: 
Wednesday, October 25, 2023

Muddy Waters has again attempted to mislead their readers and manipulate the share price for Muddy Waters’ benefit with gross inaccuracies.

Key Points: 
  • Muddy Waters has again attempted to mislead their readers and manipulate the share price for Muddy Waters’ benefit with gross inaccuracies.
  • Muddy Waters is comparing apples to oranges and even concedes that the data likely is not comparable.
  • First, as Muddy Waters acknowledges, Sunrun’s customer count is based on installations, whereas EIA data is based on assets that are already placed in operation.
  • Muddy Waters is trying to compare all costs incurred for Customer purchase systems to only the capitalized costs to create Subscribers.

Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial

Retrieved on: 
Wednesday, October 25, 2023

This is the second installment of the EUR 3.5 million in unconditional funding agreed with Atlas allowing the Company to reach the topline data of the Phase 2, Part B of the KALAHARI trial, expected by the end of this year.

Key Points: 
  • This is the second installment of the EUR 3.5 million in unconditional funding agreed with Atlas allowing the Company to reach the topline data of the Phase 2, Part B of the KALAHARI trial, expected by the end of this year.
  • Under the terms of the amended Subscription Agreement, Atlas has waived the market capitalization and liquidity conditions for up to EUR 3.5 million in mandatorily convertible bonds to be issued before the topline data is received by the end of 2023.
  • Under the Funding Program, Atlas has committed to up to EUR 20 million in funding over a 24-month period, of which it has now subscribed to EUR 10.5 million, leaving a remainder of EUR 9.5 million of which the conditions are waived for EUR 1 million.
  • Tom Graney, CEO of Oxurion, said: “Oxurion remains confident in reaching the key catalyst of reporting the topline data from the KALAHARI trial this year without additional capital, thanks to the sustained support from Atlas.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Friday, October 20, 2023

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,879,124,260 outstanding ordinary shares carrying voting rights (compared to 2,758,351,314 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Retrieved on: 
Tuesday, October 10, 2023

Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.

Key Points: 
  • Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase.
  • This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.
  • Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 2,758,351,314 outstanding ordinary shares carrying voting rights (compared to 2,667,771,604 outstanding ordinary shares previously).
  • This number will be used as the denominator for the calculation of the percentages of shareholdings.

IDTechEx Reports on White Biotechnology: Key Technology Trends Reshaping Its Growth

Retrieved on: 
Thursday, October 12, 2023

With improvements in biotechnology tools and processes comes the ability to produce everything from commodity chemicals to high-performance materials through white biotechnology.

Key Points: 
  • With improvements in biotechnology tools and processes comes the ability to produce everything from commodity chemicals to high-performance materials through white biotechnology.
  • This begs the question – what are the technology trends reshaping white biotechnology' future?
  • In IDTechEx's comprehensive report " White Biotechnology 2024-2034 ", numerous technology innovations are critically assessed to analyze the future of white biotechnology.
  • Additionally, IDTechEx provides a comprehensive examination of critical application areas, discussion of technology trends, and in-depth market and economic analysis.